Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and
safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative
disorders.